Lab-Grown Sperm Creates Embryos in World-First Fertility Breakthrough

SALT LAKE CITY, May 13, 2026 – In a landmark announcement that could redefine the boundaries of reproductive medicine, Salt Lake City-based Paterna Biosciences today declared it has achieved a world-first: the creation of functional human sperm entirely in a laboratory setting. The company reports that these lab-grown gametes have successfully fertilized human eggs, resulting in the formation of viable early-stage embryos.

This development represents a potential paradigm shift for treating male infertility, a condition contributing to roughly half of all conception difficulties for couples. For nearly a century, the scientific community has pursued in vitro spermatogenesis (IVS)—the process of creating sperm outside the body—with success remaining elusive in humans, confined only to animal models. Paterna's announcement suggests they have finally cracked the code, offering a beacon of hope to millions.

"For the first time, we can offer men who've been told there are no options a path forward that starts with their own biology," said Dr. Alexander Pastuszak, Co-Founder and CEO of Paterna Biosciences, in a statement. "That is not a small thing, and the science is groundbreaking."

A Century-Old Quest Solved?

The team at Paterna, a company founded by reproductive urologists and stem cell scientists, claims their breakthrough stems from successfully decoding and replicating the complex biological signals the body uses to mature sperm. The process begins with a small testicular biopsy from a patient. From this tissue, spermatogonial stem cells are isolated and cultivated in a lab environment that meticulously mimics the natural developmental journey, coaxing them into becoming fully formed sperm.

Paterna asserts that the resulting sperm are "structurally and genetically indistinguishable" from those produced naturally and that the embryos created show development comparable to those from standard In Vitro Fertilization (IVF). However, these groundbreaking claims, announced via a press release, have not yet been published in a peer-reviewed scientific journal or independently replicated. This critical step will be essential for validating the findings and ensuring the safety and efficacy of the technique. The history of science is littered with premature announcements; in 2015, a French company made similar claims that were later met with skepticism when full functional data was not presented.

The Path to Clinic: Hurdles and Hope

Paterna's initial focus is on the most challenging cases of male infertility: men with non-obstructive azoospermia (NOA), a condition where the body produces no sperm at all. Affecting up to 20 percent of infertile men, their current best hope is an invasive, multi-hour surgery to search for any trace of sperm, a procedure with no guarantee of success. Paterna's technology would replace this ordeal with a standard office biopsy, a far less daunting prospect.

The company also anticipates its platform will serve men with low sperm count and quality, for whom conventional IVF often fails. Despite the promise, the path from a lab breakthrough to a clinical reality is long and fraught with regulatory challenges. Paterna hopes to enter international markets by 2029 and gain initial FDA approval soon after, with plans to begin early-phase studies in 2025.

However, novel reproductive technologies, collectively known as in vitro gametogenesis (IVG), operate in a complex regulatory space. Experts and bioethics bodies like the UK’s Human Fertilisation and Embryology Authority (HFEA) have pointed to a potential "regulatory gap," where existing laws are insufficient to govern the creation of human life in a dish. The primary concern is safety—proving, with absolute certainty, that this method does not introduce subtle genetic or epigenetic errors that could be passed down through generations is a monumental task that will require years of rigorous testing.

Fertility's Next Fortune

The scientific and human implications are matched by the enormous market potential. The global male infertility market was valued at over $4 billion in 2023 and is projected to climb towards $6 billion by 2030. It is a field that has seen minimal innovation compared to female reproductive health, which has advanced significantly over the past three decades.

Investors have taken notice of the opportunity to disrupt this stagnant market. Paterna Biosciences has already raised $11.4 million and is currently seeking a $12 million Series A round. Its backers include a roster of strategic heavyweights. IVIRMA Global, the world's largest IVF clinic network and part of the investment firm KKR, is a key investor, signaling strong confidence from the industry that would ultimately deliver this treatment. The prestigious Mayo Clinic has also invested and included Paterna in its MedTech Accelerator program. The company's seed round was led by SpringTide Ventures, a venture capital firm that praised Paterna's potential to dramatically improve outcomes in a field desperate for innovation.

This infusion of capital and strategic support underscores the belief that Paterna's technology could not only create a new treatment category but also reshape the economics of the multi-billion-dollar fertility industry. While Paterna appears to be the first to announce functional human sperm, other startups like Conception and Gameto are working on the other side of the equation—creating lab-grown human eggs—signaling a new and well-funded technological race to reshape human reproduction.

Beyond Biology: The New Ethical Horizon

As science sprints forward, it raises profound ethical and societal questions that we are only beginning to contemplate. The ability to create human sperm—and eventually eggs—in a lab opens up scenarios once confined to science fiction. On one hand, it offers remarkable possibilities, potentially allowing same-sex couples to have biological children genetically related to both partners. On the other hand, it raises the specter of "designer babies," where parents could select for non-medical traits, potentially deepening social inequalities between those who can afford genetic enhancements and those who cannot.

Bioethicists and organizations like the Nuffield Council on Bioethics have urged for a broad public dialogue to grapple with these issues before the technology becomes a clinical reality. The questions are complex and deeply personal: What are the rights of a child born from this technology? How do we define parenthood in a world of "multiplex parenting," where a child could have genetic material from more than two people? As the science accelerates, society now faces the profound task of deciding how to navigate the new map of human creation that is being drawn.